

Conclusion* We have developed the first robust model of disease-specific survival after recurrence stratifying relapsing cervical cancer patients according to their risk profile using six traditional prognostic markers. The strongest factor related to the length of post-recurrence survival was the largest size of the primary tumour, followed by the presence of symptoms at the time of diagnosis, which remained significant even after correction for lead-time bias.

950

SENSITIVITY AND FALSE NEGATIVITY OF SLN FROZEN SECTION HISTOLOGICAL EVALUATION IN THE SENTIX TRIAL (CEGOG-CX01; ENGOT-CX2; NCT02494063)

¹R Kocian*, ²C Kohler, ¹S Bajsová, ¹S Sebestova, ³I Zapardiel, ⁴GDI Martino, ⁵L Van Lonkhuijzen, ¹B Sehnal, ³O Arencibia Sanchez, ³B Gil-Ibanez, ⁴F Martinielli, ¹J Presl, ¹L Minar, ¹R Marek, ⁶P Kascak, ¹P Havelka, ¹M Michal, ⁷T Van Gorp, ¹K Nemejcova, ¹D Cibula. ¹Czech Republic; ²Germany; ³Spain; ⁴Italy; ⁵Netherlands; ⁶Slovakia; ⁷Belgium

10.1136/ijgc-2021-ESGO.79

Introduction/Background* SENTIX is a prospective cohort multicentric international study on sentinel lymph node (SLN) biopsy without pelvic lymph node dissection (PLND) in patients with early-stage cervical cancer. SLN frozen section (FS) and pathological ultrastaging were mandatory by the protocol. Samples from SLN were reviewed centrally for pathological assessment quality control. Only sites experienced in SLN biopsy technique could join the trial.

Methodology In total, 47 sites from 18 countries participated in the trial. Patients with FIGO 2009 stages T1A1/LVSI+ – T1B1 (<4 cm or ≤ 2 cm for fertility sparing), with common tumour types and no suspicious lymph nodes on imaging were

Abstract 950 Table 1 Patient's characteristics (N=733)

| Parameter | | N (%) / median (5-95 th percentile) |
|---------------------------------------|------------------------------|--|
| Age | | 43 (29; 67) |
| | ≤ 40 | 294 (40.1%) |
| | 41-60 | 339 (46.2%) |
| | 61+ | 100 (13.6%) |
| BMI | ≤ 25 | 418 (57.0%) |
| | 25-30 | 169 (23.1%) |
| | 30+ | 141 (19.2%) |
| | NA | 5 (0.7%) |
| | ECOG PS | 0 |
| | 1 | 29 (4.0%) |
| Diagnostic method | Biopsy | 331 (45.2%) |
| | Conization | 399 (54.4%) |
| | NA | 3 (0.4%) |
| Enrolled patients by site's size: | | |
| | ≤10 | 126 (17.2%) |
| | 11-20 | 81 (11.1%) |
| | 21+ | 526 (71.8%) |
| Maximum preoperative tumour size (mm) | ≤ 20 | 471 (64.2%) |
| | 20.1-40 | 262 (35.8%) |
| Preoperative tumour stage (FIGO 2009) | 1A1 | 32 (4.4%) |
| | 1A2 | 54 (7.4%) |
| | 1B1 | 647 (88.2%) |
| Tumour grade | G1 | 179 (24.4%) |
| | G2 | 373 (50.9%) |
| | G3 | 157 (21.4%) |
| | NA | 24 (3.3%) |
| LVSI | yes | 448 (61.1%) |
| Tumour type | SCC | 508 (69.3%) |
| | AC | 210 (28.6%) |
| | AS | 9 (1.2%) |
| | NA | 6 (0.8%) |
| Excluded: | | |
| Preoperatively | Surgery cancelled | 4 (0.5%) |
| | ICF withdrawn | 4 (0.5%) |
| Intraoperatively | SLN not detected bilaterally | 55 (7.5%) |
| | > 1B1 | 12 (1.6%) |
| Other | | 8 (1.1%) |

Abstract 950 Table 2 SLN status assessed by frozen section and final ultrastaging (N=650)

| Type of SLN involvement | SLN status (No. of patients) | | | SLN frozen section outcome (%) | | |
|-------------------------|------------------------------|--------------|-------------------|--------------------------------|------------------|-------|
| | Frozen section | Ultrastaging | Final SLN status* | Sensitivity | False negativity | NPV |
| MAC | 44 | 9 | 53 | 83.0% | 17.0% | 98.5% |
| MIC | 4 | 26 | 30 | 13.3% | 86.7% | 95.7% |
| ITC | 0 | 19 | 19 | 0.0% | 100.0% | 96.8% |
| MAC + MIC | 48 | 35 | 83 | 57.8% | 42.2% | 94.2% |
| MAC + MIC + ITC | 48 | 54 | 102 | 47.1% | 52.9% | 91.0% |

registered in the trial. Patients remained in the trial after the surgery if SLN were detected on both sides of the pelvis and if SLN were negative on FS histological evaluation. Blue dye, radioactive tracer, indocyanine green or their combinations were all eligible tracers for SLN detection. Intraoperative SLN pathological processing consisted of SLN examination in one randomly selected slice. SLN ultrastaging protocol included a complete processing of all SLN tissue in slices of 2 mm thickness, 2 sections in 150 µm from each block until no tissue left, one stained with H&E and second examined immunohistochemically.

Result(s)* Altogether 733 patients were registered until Sentix enrolment closure in October 2020, 83 patients were excluded (table 1) and 650 patients was analysed. Patients' characteristics are shown in table 1. Bilateral SLN detection rate reached 95%. FS detected macrometastases (MAC) in 44 cases and micrometastasis (MIC) in 4 cases. SLN ultrastaging found additional 9 cases with MAC, 26 with micrometastases (MIC) and all 19 cases with isolated tumor cells (ITC). Sensitivity of FS was 83.0% for the detection of MAC, 57.8% for pN1 status (MAC or MIC) and 47.1% for any type of SLN involvement (MAC, MIC, ITC). Table 2.

Conclusion* High bilateral detection rate of 95% was achieved in Sentix sites experienced in the SLN biopsy technique. Intraoperative pathological assessment of SLN failed to detect majority of MIC (86.7%), all cases with ITC and 42.2% with pN1 (MIC or MAC).

955

WATER-JET DISSECTION IN NERVE-SPARING RADICAL HYSTERECTOMY: POSTOPERATIVE OUTCOMES

S Mukhtarulina*, M Meshkova, O Trushina, H Maltsgova, E Novikova. P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC, the department of gynecologic oncology, Moscow, Russian Federation

10.1136/ijgc-2021-ESGO.80

Introduction/Background* The development of a nerve-sparing technique of radical hysterectomy leads to a significant functional improvement after surgical treatment of cervical cancer. However, the risk of nerve fibers damage remains high because of difficulties in recognition of elements of the autonomic nervous system. One of approaches for precise nerve dissection is tissue-selective dissection with a water-jet. The main advantage of this method is selective dissection and preservation of nerve fibers and vessels with minimal deformation of the surrounding tissue. This study was aimed to evaluate

functional results after nerve sparing radical hysterectomy (RH type C1) in patients with stage IB1-IIA cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO 2018) staging system.

Methodology Inclusion criteria consisted of the following: histopathologically proven primary cervical cancer of squamous carcinoma, adenocarcinoma or adenosquamous carcinoma, stage IB1-IIA cervical cancer, the lack of preoperative radiation therapy or chemotherapy, ECOG PS 0-1 and normal bladder filling. The main group consisted of 26 patients with stage IB1-IIA cancer after RH type C1 using the water-jet technique. The hypogastric nerve, pelvic splanchnic nerves S2-S4 and vesicular branches of these plexus were selectively isolated under water pressure of 35 Bar. The comparison group A included 79 patients who underwent RH type C1 with the traditional technique. The comparison group B included 52 patients who accepted radical hysterectomy RH type C2.

Result(s)* The average duration of urinary bladder catheterization after surgery in the main group and comparison groups A and B was 2.9 ± 1.8 ; 6.9 ± 3.8 and 16.1 ± 10.9 days, respectively ($p < 0.05$). The average time for recording of residual urine volume less than 100 ml in the main group amounted to 3.8 ± 1.2 days, in the comparison group A – 10.2 ± 7.5 days, and in the comparison group B – 21.2 ± 20.8 days ($p < 0.05$). In the main group patients had no sign of bladder dysfunction whereas in comparison groups A and B patients encountered these symptoms in 7.6% and 26.2% of cases, respectively ($p < 0.05$).

Conclusion* The first results suggest that using the water-jet technique in tissue incision contributes to the most atraumatic dissection of the autonomic nervous system. Thus, RH type C1 with water-jet dissection result in restoration of lower urinary tract functions in a shorter time.


959

CHALLENGES IN LOWER LIMB LYMPHOEDEMA ASSESSMENT BASED ON LIMB VOLUME CHANGE: LESSONS LEARNT FROM THE SENTIX PROSPECTIVE MULTICENTRE STUDY

^{1,2}M Borčinová*, ^{1,2}R Kocián, ³V Ragošch, ⁴J Jarkovsky, ^{2,5}S Bajsová, ^{2,6}R Pilka, ⁷B Gil Ibanez, ⁸S Garrido-Mallach, ^{2,9}J Presl, ¹⁰A Palop Moscardó, ¹¹S Tingulstad, ^{12,13}B Vergote, ^{2,14}M Redecha, ¹⁵F Raspagliesi, ¹⁶W Szatkowski, ¹⁷M Pakiz, ¹⁸LC Snyman, ³K Siegler, ^{1,2}D Cibula. ¹First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Prague, Czech Republic; ²Central and Eastern European Gynecologic Oncology Group, CEEGOG, Czech Republic; ³Asklepios-Clinic Hamburg, Department of Special Operative and Oncologic Gynaecology, Germany; ⁴Faculty of Medicine, Masaryk University, Institute of Biostatistics and Analyses, Brno, Czech Republic; ⁵University Hospital Ostrava, Department of Obstetrics and Gynecology, Ostrava, Czech Republic; ⁶Palacky University, University Hospital Olomouc, Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic; ⁷Hospital Clinic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Unit of Gynecological Oncology, Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Barcelona, Spain; ⁸La Paz University Hospital, Gynecologic Oncology Unit, Madrid, Spain; ⁹University Hospital in Pilsen, Department of Obstetrics and Gynecology, Pilsen, Czech Republic; ¹⁰Instituto Valenciano de Oncologia (IVO), Gynecology Department, Valencia, Spain; ¹¹Trondheim University Hospital, Trondheim, Norway; ¹²University Hospital Leuven, Leuven Cancer Institute, Department of Gynecology and Obstetrics, Leuven, Belgium; ¹³Belgium and Luxembourg Gynaecological Oncology Group, BGOG; ¹⁴University Hospital, Comenius University, Department of Gynaecology and Obstetrics, Bratislava, Slovakia; ¹⁵Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ¹⁶M. Skłodowska-Curie Memorial Institute, Krakow, Poland; ¹⁷University medical Centre Maribor, Maribor, Slovenia; ¹⁸Kalafong Provincial Tertiary Hospital, Pretoria, South Africa

10.1136/ijgc-2021-ESGO.81

Introduction/Background* Lower limb lymphoedema (LLL) is the most disabling adverse effect of surgical staging of pelvic lymph nodes. In studies, LLL is often assessed by calculation of limb volumes based on five circumference measurements. However, the lack of standardisation of this method hinders direct comparison between the studies and makes LLL



Abstract 959 Figure 1 Distribution of the limb volume change (from preoperative assesment; LVC) of right and left lower limb during the follow-up-period. Each dot on the violin plot represents the LVC of one patient's limb. 6M: six months post-surgery; 12M months post-surgery; 18M months post-surgery; 24M: 24 months post-surgery.